Resources

BioOrbit is enabling pharmaceutical drugs to be manufactured in space at scale

It has been an extremely challenging time for biotech post COVID-19 boom, but our Q1 financing report offers hope with continued positive momentum.

‍Nemera and Therakind have partnered on DriDose® dry powder intranasal technology.

In this blog, Jaime Eaton, reflects on this month's Community Connects series, bringing together diverse expertise to tackle the most pressing challenges in our sector.

The launch of the NIHR Industry hub last week, the launch of UKRI/Innovate strategy this Thursday and a landmark Mansion House event tomorrow all signal forward momentum on Industrial Strategy.

Rare Disease Day on Saturday was a moment to reflect on the momentum building, and to check in on the progress of the UK Rare Disease Framework.

In this blog, Emily Klein reflects on the importance of Rare Disease Day in bringing visibility to those affected by a rare condition and serving as a focal point for advocacy in this space.

With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.

Complement Therapeutics GmbH (CTx) has received Clinical Trial Authorisation (CTA) approval in the United Kingdom for CTx001.

As 2026 shapes up to an unpredictable year, our policy experts have provided more grounding for what the life sciences sector should expect over the next 12 months. This is the second and final part of our 2026 outlook series. 

J.P. Morgan’s healthcare conference may be wrapped up, but it has set some tangible momentum and without doubt a more buoyant mood for global life sciences going into 2026.

An acknowledgment from Astrea Bioseparations celebrating LIB Therapeutics' achievement of FDA approval for LEROCHOL™, including some collaboration efforts.

As we settle into the rhythms of daily life and gather our thoughts about the year ahead, our policy experts have weighed in on what the life sciences sector might expect in 2026.

Amici Procurement Solutions Rebrands as MyAmici. The rebrand reflects the organization’s strategic evolution from a procurement-focused provider to a comprehensive, end-to-end LabOps platform supporting biotech, medtech, and life-science organisations across every stage of growth.

Complement Therapeutics is one of the leading new gene therapy companies entering into clinical trials. Based on research from the University of Manchester, the company's lead candidate CTx001 is a novel adeno-associated virus (AAV)-based gene therapy targeting an advanced form of dry AMD that leads to irreversible vision loss, with limited therapeutic options. With strong funding and an experienced management team, Complement has made rapid progress and this Fast Track designation comes after IND clearance in December.

In this blog, Blood Cancer UK reflects on a year of partnership with BIA — from raising vital funds and forging new connections in life sciences, to amplifying the voice of people affected by blood cancer across the UK.

BIA thought leadership takes centre stage with two key reports published: last week saw the release of 'From innovation to impact: unlocking patient access to innovative rare disease medicines', and today 'UK cell and gene therapy: driving efficiencies and innovation' celebrates real-world UK success.

The BioIndustry Association (BIA) released From Innovation to Impact: Unlocking Patient Access to Innovative Rare Disease Medicines, calling for new pathway to give UK patients access to innovative rare disease medicines.